Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gedeon Richter Pledges New Markets For Teriparatide Biosimilar

Debuted In Three New Markets In Last 12 Months

Executive Summary

Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.

You may also be interested in...



Gedeon Richter Tipped For M&A As Cash Pile Rises

Gedeon Richter is keeping a keen eye on further business development opportunities, including M&A. The company is also continuing to tackle the impact of Russia’s invasion of Ukraine, observing that “there’s still not very much clarity on how the situation will evolve.”

Richter’s Biosimilar Costs ‘Took Up A Lot Of Resources Last Year’

Hungary’s Gedeon Richter is continuing to divert the greatest proportion of its R&D cash to biosimilars. Management updated on its pipeline and broader group prospects amid Russia’s military invasion of Ukraine.

Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB150971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel